Search results for "Aryl"

showing 10 items of 810 documents

Response of pineal serotonin N-acetyltransferase activity in male guinea pigs exposed to light pulses at night.

1988

Serotonin N-acetyltransferase (NAT), which is crucial for the formation of melatonin, undergoes a typical day/night rhythm in the pineal gland with low levels during daytime and high levels at night. Short pulses of light given at night have been shown to rapidly depress NAT activity in some species, but not in others, the reasons for this difference being unclear. As diurnality and nocturnality of the experimental animals may play a role and since diurnally active animals have been little investigated in this respect, in the present study the diurnally active guinea pig was investigated. Male guinea pigs kept under a lighting regimen of LD 12:12 (lights off at 1700 hrs) were killed between…

Acetylserotonin O-MethyltransferaseMaleendocrine systemmedicine.medical_specialtyLightArylamine N-AcetyltransferaseGuinea PigsBiologyPineal GlandNocturnalityMelatoninPineal glandSpecies SpecificityAcetyltransferasesInternal medicineCricetinaemedicineAnimalsDiurnalityCircadian rhythmBiological PsychiatrySheepMesocricetusArvicolinaefungiSciuridaeRatsPsychiatry and Mental healthEndocrinologymedicine.anatomical_structureNeurologyAcetylserotonin O-methyltransferaseDarknessNeurology (clinical)SerotoninGerbillinaemedicine.drugJournal of neural transmission
researchProduct

Neuropeptide Y effects on pineal melatonin synthesis in the rat

1987

Neuropeptide Y (NPY)-like immunoreactivity is present in the rodent pineal gland. To elucidate possible effects on pineal melatonin synthesis NPY (5 nmol/kg body wt.) was injected into the common carotid artery of male rats. Activities of the melatonin biosynthetic enzymes, serotonin N-acetyltransferase (NAT) and hydroxyindole-O-methyltransferase (HIOMT) were determined by means of radioenzymatic methods. Intact light-exposed animal showed increased NAT activity at day- and at nighttime. Blinded animals showed a more than 10-fold reduction of NAT activity after nocturnal NPY injections. HIOMT activity was only slightly influenced at either time. These results are discussed in terms of the p…

Acetylserotonin O-MethyltransferaseMaleendocrine systemmedicine.medical_specialtyNeuroeffectorArylamine N-AcetyltransferaseBiologyPineal GlandMelatoninNorepinephrinePineal glandNorepinephrineInternal medicinemental disordersmedicineAnimalsNeuropeptide YMelatoninArylamine N-acetyltransferaseGeneral NeuroscienceRats Inbred StrainsNeuropeptide Y receptorhumanitiesRatsReceptors AdrenergicEndocrinologymedicine.anatomical_structureAcetylserotonin O-methyltransferaseSerotoninmedicine.drugNeuroscience Letters
researchProduct

Effects of an earth-strength magnetic field on pineal melatonin synthesis in pigeons

1987

Acetylserotonin O-Methyltransferasemedicine.medical_specialtyArylamine N-AcetyltransferaseChamp magnetiqueMethyltransferasesGeneral MedicineBiologyPineal GlandMagnetic fieldPineal melatoninMelatoninMagneticsPineal glandmedicine.anatomical_structureEndocrinologyAcetyltransferasesAcetylserotonin O-methyltransferaseInternal medicinemedicineAnimalsColumbidaeEcology Evolution Behavior and SystematicsMelatoninmedicine.drugNaturwissenschaften
researchProduct

IMPROVE-IT: what have we learned?

2016

Purpose of review: Recent studies and dyslipidemia treatment guidelines indicate that combination lipid-lowering therapy is frequently needed and its use has increased in recent years. Ezetimibe and simvastatin as a fixed dose is an efficacious treatment choice based on positive results of the recent IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). In this review, we discuss recent controversies surrounding ezetimibe and provide clinical perspective on the results of the IMPROVE-IT study. Recent findings: IMPROVE-IT is the first trial that demonstrates a significant clinical benefit of a nonstatin hypolipidemic agent (ezetimibe) used in combination with sta…

Acute coronary syndromeSimvastatinHypercholesterolemia030204 cardiovascular system & hematologyPharmacologyFixed dose03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePharmacotherapyEzetimibeMedicineHumansLow-density lipoprotein cholesterol030212 general & internal medicineAcute Coronary SyndromeIMPROVE-IT trialbusiness.industryCholesterolAnticholesteremic AgentsAnticholesteremic Agentsnutritional and metabolic diseasesCholesterol LDLmedicine.diseaseCardiovascular riskEzetimibeTreatment OutcomechemistrySimvastatinAzetidinesDrug Therapy CombinationHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessCardiology and Cardiovascular MedicineDyslipidemiamedicine.drugCurrent opinion in cardiology
researchProduct

Pharmacological Interventions on Asymmetric Dimethylarginine, a Clinical Marker of Vascular Disease

2011

The aim of this paper is to review the latest data on the pharmacological modulation of asymmetric dimethylarginine in human disease. When the terminal nitrogens of the guanidine portion of an arginine become methylated through the action of N-methyl transferases, two chemically close, but physiologically different amino acids are synthesized: symmetric and asymmetric dimethylarginine. The vascular origin of asymmetric dimethylarginine and its inhibitory activity on endothelial nitric oxide synthase give it an important role in certain diseases in which microcirculation is compromised: hypertension, atherosclerosis, inflammatory bowel disease, and diabetes. This review discusses the role th…

Adrenergic Antagonistsmedicine.medical_specialtyAngiotensinsNitric Oxide Synthase Type IIIArginineHypercholesterolemiaPeroxisome Proliferator-Activated ReceptorsHyperhomocysteinemiaReceptors Cytoplasmic and NuclearPeroxisome proliferator-activated receptorPharmacologyArginineBiochemistryNitric oxideDiabetes Complicationschemistry.chemical_compoundInternal medicineDrug DiscoveryAdrenergic antagonistmedicineHumansVascular DiseasesPharmacologychemistry.chemical_classificationVascular diseaseMicrocirculationOrganic Chemistrymedicine.diseaseAngiotensin IIEndocrinologychemistryHypertensionMolecular MedicineKidney DiseasesFarnesoid X receptorHydroxymethylglutaryl-CoA Reductase InhibitorsAsymmetric dimethylarginineCurrent Medicinal Chemistry
researchProduct

Anaesthetic techniques to prevent perioperative stroke.

2013

Different techniques and interventions that can be used by an anaesthesiologist to minimize the perioperative stroke risk are summarized.The most important risk factors for perioperative stoke are not modifiable, for example previous stroke or renal failure, but they can be used to identify patients with a high risk for perioperative stroke. The antiplatelet therapy should be continued in patients with a high risk for cardiovascular thrombosis. This might be true even for operations in which bleeding should be strictly avoided such as eye surgery. One of the most recent neuroprotective approaches is the remote ischaemic preconditioning.Perioperative stroke increases morbidity and mortality …

Adrenergic beta-AntagonistsPsychological interventionMEDLINEPerioperative CareAdrenergic beta-AntagonistsPostoperative ComplicationsRisk FactorsMonitoring IntraoperativemedicineAnimalsHumansAnesthesiacardiovascular diseasesIntraoperative ComplicationsIschemic PreconditioningStrokePerioperative strokeAnestheticsbusiness.industryAnticoagulantsPerioperativemedicine.diseaseCerebrovascular CirculationStrokeAnesthesiology and Pain MedicineAnesthesiaCerebrovascular CirculationIschemic preconditioningHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessCurrent opinion in anaesthesiology
researchProduct

Mutational analysis of 105 mucopolysaccharidosis type VI patients

2007

Mucopolysaccharidosis type VI (MPS VI; Maroteaux-Lamy syndrome) is a lysosomal storage disorder caused by mutations in the N-acetylgalactosamine-4-sulfatase (arylsulfatase B, ARSB) gene. ARSB is a lysosomal enzyme involved in the degradation of the glycosaminoglycans (GAG) dermatan and chondroitin sulfate. ARSB mutations reduce enzyme function and GAG degradation, causing lysosomal storage and urinary excretion of these partially degraded substrates. Disease onset and rate of progression is variable, producing a spectrum of clinical presentation. In this study, 105 MPS VI patients—representing about 10% of the world MPS VI population—were studied for molecular genetic and biochemical parame…

AdultArylsulfatase BAdolescentN-Acetylgalactosamine-4-SulfataseMPS VIDNA Mutational AnalysisNonsense mutationMucopolysaccharidosis type VIBiologyPolymorphism Single NucleotideGenetic HeterogeneityAge DistributionGene FrequencyGenotypeGeneticsmedicineHumansMissense mutationGenetic TestingChildCells CulturedGenetics (clinical)mucopolysaccharidosis type VIGlycosaminoglycansGeneticsMucopolysaccharidosis VIGenetic heterogeneityMucopolysaccharidosis VIMiddle Agedmedicine.diseasearylsulfatase BMaroteaux–Lamy syndromeDisease ProgressionARSBMaroteaux-LamyHuman Mutation
researchProduct

Genotype and allele frequencies of isoniazid-metabolizing enzymes NAT2 and GSTM1 in Latvian tuberculosis patients

2016

Pharmacogenomic testing of tuberculosis drug-metabolizing enzyme genes was proposed as a strategy to identify patients at risk for suboptimal responses to medications. However, variations of the genotype frequencies among ethnic groups exist and new alleles are been identified. The aim of this study was to identify polymorphisms of genes encoding metabolic enzymes NAT2 and GSTM1 in tuberculosis patients in Latvia and to estimate the frequency of NAT2 slow acetylator and GSTM1 null genotypes. In total, 85 DNA samples were genotyped, all individuals were Caucasian. An ethnic heterogeneity reflecting the multiethnic population of the country was observed. 49 patients were Latvians, 30 were Rus…

AdultMale0301 basic medicineMicrobiology (medical)TuberculosisGenotypeArylamine N-AcetyltransferaseAntitubercular AgentsBiologyYoung Adult03 medical and health sciencesGene FrequencyGenotypeIsoniazidmedicineHumansTuberculosisPharmacology (medical)AlleleGenotypingAllele frequencyAgedGlutathione TransferaseGeneticsPolymorphism GeneticIsoniazidMiddle Agedmedicine.diseaseLatviaGenotype frequency030104 developmental biologyInfectious DiseasesFemalePharmacogeneticsmedicine.drugJournal of Infection and Chemotherapy
researchProduct

Lomitapide affects HDL composition and function

2016

Abstract Background Lomitapide reduces low-density lipoprotein-cholesterol (LDL-C) but also high-density lipoprotein-cholesterol (HDL-C) levels. The latter may reduce the clinical efficacy of lomitapide. We investigated the effect of lomitapide on HDL-C levels and on cholesterol efflux capacity (CEC) of HDL in patients with homozygous familial hypercholesterolemia (HoFH). Methods and results Four HoFH patients were treated with increasing dosages of lomitapide. Lomitapide decreased LDL-C (range −34 to −89%). Total HDL-C levels decreased (range −16 to −34%) with a shift to buoyant HDL. ABCA1-mediated CEC decreased in all patients (range −39 to −99%). The changes of total, ABCG1- and SR-BI-me…

AdultMale0301 basic medicinemedicine.medical_specialtySettore MED/09 - Medicina InternaHDLHomozygous familial hypercholesterolemiaFamilial hypercholesterolemia030204 cardiovascular system & hematologyHyperlipoproteinemia Type IIYoung Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineHumansMedicineIn patientClinical efficacyHyperlipoproteinemia Type IICholesterolbusiness.industryCholesterol HDLHomozygotenutritional and metabolic diseasesCholesterol LDLCholesterol efflux capacityAtherosclerosismedicine.diseaseCholesterol lowering drugsLomitapideLomitapideCholesterolPhenotypeTreatment Outcome030104 developmental biologyEndocrinologychemistryBenzimidazolesFemalelipids (amino acids peptides and proteins)Composition (visual arts)Cholesterol lowering drugHydroxymethylglutaryl-CoA Reductase InhibitorsLipoproteins HDLCardiology and Cardiovascular MedicinebusinessATP Binding Cassette Transporter 1Atherosclerosis
researchProduct

Acute Myocardial Infarction and Proinflammatory Gene Variants

2007

We identified four genetic risk sets for acute myocardial infarction (AMI) from information on functional gene variants that favor inflammation or modulate cholesterol metabolism: IL6 -174 G/C, TNF -308 G/A, IL10 -1082 G/A, SERPINA3 -51 G/T, IFNG +874 T/A, HMGCR -911 C/A, and APOE ε2/3/4; 316 patients and 461 healthy subjects, all Italian. Putative risk alleles are shown underlined. The sets were identified using grade-of-membership analysis. Membership scores in the sets are automatically generated for individuals. The ''low intrinsic risk'' set had alleles that downregulate inflammation and cholesterol synthesis (IL6, TNF, ILl0, HMGCR). ''AMI across a broad age range'' carried multiple pr…

AdultMaleApolipoprotein EAdolescentMyocardial InfarctionGeneral Biochemistry Genetics and Molecular BiologyProinflammatory cytokinePathogenesischemistry.chemical_compoundApolipoproteins EHistory and Philosophy of SciencemedicineHumansGenetic Predisposition to DiseaseMyocardial infarctionAge of OnsetAlleleAllelesSerpinsAgedAged 80 and overbusiness.industryCholesterolGeneral NeuroscienceMiddle Agedmedicine.diseaseMiddle ageInterleukin 10CholesterolchemistryAMI Grade of Membership Genetic profile IL6 -174 G/C TNF -308 G/A IL10 -1082 G/A SERPINA3 -51 G/T IFNG +874 T/A HMGCR -911 C/A APOE ε2/3/4Acute DiseaseImmunologyCytokinesFemaleHydroxymethylglutaryl CoA Reductaseslipids (amino acids peptides and proteins)businessAnnals of the New York Academy of Sciences
researchProduct